HMBD-002
HMBD-002 is an Fc-independent, non-depleting IgG4 subclass antibody that targets VISTA and VSIG3. It is widely used in research related to various solid tumors, including colon cancer, triple-negative breast cancer, and non-small cell lung cancer. HMBD-002 blocks the interactions of VISTA with VSIG3 and LRIG1, relieves immunosuppression without depleting VISTA-positive cells, activates the cytotoxic program of CD8+ T cells, and drives the type I interferon signaling pathway. HMBD-002 reprograms tumor-associated macrophages to the M1 phenotype, reduces tumor infiltration of inhibitory myeloid cells, thereby significantly inhibiting tumor growth and improving survival. HMBD-002 is well tolerated in rodent and non-human primate animal models.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Human IgG4 kappa
Human
HMBD-002 (1-10 μg/mL) reverses VSIG3-mediated suppression of activated human PBMCs, with greater activity observed at 10 μg/mL compared to 1 μg/mL in a 1:2 VSIG3-Fc to αCD3 coating ratio assay[1].
HMBD-002 (1-30 μg/mL) enhances immune activation in human PBMC MLRs, significantly increasing TNF-α and IFN-γ production at a concentration of 30 μg/mL[1].
HMBD-002 inhibits the interaction between recombinant VISTA and LRIG1 proteins with an IC50 of 3.4 nM[3].
HMBD-002 (1-10 µg/mL; 24 hours at 37°C) reverses VSIG3-mediated suppression of IFN-γ secretion from anti-CD3-activated human PBMCs, with significant restoration of IFN-γ levels at 1 µg/mL and 10 µg/mL[3].
HMBD-002 (1-30 µg/mL; 96 hours at 37°C) polarizes the immune milieu toward a proinflammatory Th1/Th17 response in human allogenic MLRs, inducing significant dose-dependent increases in IFN-γ and TNF-α and enriching proinflammatory signaling pathways at 1 µg/mL, 10 µg/mL, and 30 µg/mL[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human PBMCs
-
Concentration:1-10 µg/mL
-
Incubation Time:24 hours
-
Result:Reversed VSIG3-mediated suppression of IFN-γ secretion, with significant restoration of IFN-γ levels at 1 µg/mL and 10 µg/mL.
HMBD-002 (50 µg; intratumorally; on days 7, 9, 12, 14, 16 post implantation) achieves 53% tumor growth inhibition in a BALB/c mouse orthotopic 4T1 breast cancer model[3].
HMBD-002 (25 mg/kg; i.p.; biweekly) produces 65% tumor growth inhibition in a humanized HiMouse HCT15 colorectal cancer model[3].
HMBD-002 (25 mg/kg; i.p.; biweekly) delivers 62% tumor growth inhibition in a humanized HiMouse A549 lung cancer model[3].
HMBD-002 monotherapy activates the immune system (inducing up to 4-fold increases in serum IL-2, IL-17, and IFNγ) and achieves >60% tumor growth inhibition after 15 days in a CT26 syngeneic colon cancer BALB/C mouse model, with no observable toxicity[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c mice (female; subcutaneously implanted with CT26 cells)[3]
-
Dosage:25 mg/kg
-
Administration:i.p.; biweekly
-
Result:Demonstrated 84% tumor growth inhibition (TGI) compared with vehicle.
Increased the percentage of CD11b+ MHCII+ antigen presenting cells, CD11b+ F4/80+ macrophages, and CD11C+ dendritic cells in the tumor microenvironment (TME).
Decreased the frequency of total myeloid-derived suppressor cells (CD11b+ GR1+ MHCII−) in the TME.
Showed significantly higher lysis of CT26 cells by tumor-infiltrating lymphocytes (TILs) in an ex vivo antigen recall assay.
Induced significantly higher IFN-γ levels in T cells when co-cultured with CT26 cells.
B7-H5/VISTA
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
HMBD-002 Related Classifications
HY-P992369 Related Classifications
Powered by Bioz